COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario and currently employs 28 full-time employees. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Industry: Perfumes, Cosmetics & Other Toilet Preparations Peers: Edesa Biotech Inc Nymox Pharmaceutical Corp Xenon Pharmaceuticals Inc